Abstract
Currently, there is no known clinical evidence that rituximab increases the rate of subsequent primary malignancies; however, some studies have raised the question of increased melanoma risk following rituximab treatment for non-Hodgkin lymphoma. We report three interesting cases of suspected rituximab-induced melanoma. We hypothesize that this association is secondary to rituximab-driven shifts in the immunologic balance. Based on these cases, it is possible that the number of post-rituximab melanoma cases is underreported. Further mechanistic research into individual cases and population-level studies are required to better define association and risk; however, given the increasing prevalence of oncologic and nononcologic rituximab use, awareness across all fields is essential.
Original language | English (US) |
---|---|
Pages (from-to) | 67-70 |
Number of pages | 4 |
Journal | Melanoma research |
Volume | 32 |
Issue number | 1 |
DOIs | |
State | Published - Feb 1 2022 |
Keywords
- CD20
- immune checkpoint
- lymphoma
- melanoma
- rituximab
ASJC Scopus subject areas
- Oncology
- Dermatology
- Cancer Research